Effect of Montmorillonite powder on intestinal mucosal barrier in children with abdominal Henoch-Schonlein purpura: A randomized controlled study

Medicine (Baltimore). 2018 Sep;97(39):e12577. doi: 10.1097/MD.0000000000012577.


Background: Our previous studies found that intestinal barrier function has been changed in children with abdominal Henoch-Schonlein purpura (HSP). Montmorillonite has been shown to be protective for digestive tract mucosa.

Objective: The present study aimed to investigate whether Montmorillonite powder could improve the intestinal mucosal barrier function in children with abdominal HSP.

Methods: Using a randomized controlled study design, we compared plasma levels of diamine oxidase (DAO), D-lactate, and endotoxin in children with abdominal HSP before and after Montmorillonite powder treatment.

Results: Among 28 patients in experimental group and 30 in control group, there was no significant difference in age, sex, height, weight, and course of disease between 2 groups (P > .05). Before treatment, there was no statistical difference in DAO, D-lactic acid, and endotoxin between experimental group and the control group (P > .05). However, significant differences were detected for DAO and D-lactate after treatment in comparison to before treatment in the Montmorillonite experimental group (P < .05). Such differences were not found in the control group (P > .05).

Conclusion: Montmorillonite powder is effective in the treatment of HSP via maintaining intestinal mucosal barrier function.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Amine Oxidase (Copper-Containing) / blood
  • Antidotes / therapeutic use*
  • Bentonite / therapeutic use*
  • Child
  • Endotoxins / blood
  • Humans
  • IgA Vasculitis / blood
  • IgA Vasculitis / complications
  • IgA Vasculitis / drug therapy*
  • Intestinal Mucosa / drug effects*
  • Lactic Acid / blood
  • Powders


  • Antidotes
  • Endotoxins
  • Powders
  • Bentonite
  • Lactic Acid
  • Amine Oxidase (Copper-Containing)